Biocon Biologics and Viatris receive approval for first interchangeable biosimilar Semglee
The company is eligible for 12 months exclusivity from launch
The company is eligible for 12 months exclusivity from launch
The roller coaster ride during the pandemic has taken Indian pharmaceutical industry through a lot of bitter sweet experiences.
Promising drug pipeline, focus on gene therapy and innovative digital health solutions will remain the key pillars of Bayer’s pharmaceutical business
For patients with resectable early-stage gastric and gastroesophageal junction cancers
Elevidys is currently the only approved gene therapy that targets the root cause of Duchenne
Longer-term follow up in the FLAURA2 Phase III trial confirms the favourable benefit-risk profile of this combination
The Medical Countermeasures Strategy focuses on strengthening the EU’s preparedness for health crises
New findings reveal bemarituzumab plus chemotherapy significantly improves survival in advanced gastric cancer, offering hope for targeted treatment options
Subscribe To Our Newsletter & Stay Updated